An e-Delphi study to obtain expert consensus on the level of risk associated with preventable e-prescribing events

Jude Heed1 | Stephanie Klein2 | Ann Slee3 | Neil Watson2 | Andy Husband1 | Sarah Patricia Slight4

1School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK
2The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
3NHS X, UK
4School of Pharmacy, Newcastle upon Tyne, UK

Correspondence
Jude Heed, Lecturer in Pharmacy Practice, School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK.
Email: jude.heed@newcastle.ac.uk

Aims: We aim to seek expert opinion and gain consensus on the risks associated with a range of prescribing scenarios, preventable using e-prescribing systems, to inform the development of a simulation tool to evaluate the risk and safety of e-prescribing systems (ePRaSE).

Methods: We conducted a two-round e-Delphi survey where expert participants were asked to score pre-designed prescribing scenarios using a five-point Likert scale to ascertain the likelihood of occurrence of the prescribing event, likelihood of occurrence of harm and the severity of the harm.

Results: Twenty-four experts consented to participate with 15 and 13 participants completing rounds 1 and 2, respectively. Experts agreed on the level of risk associated with 136 out of 178 clinical scenarios with 131 scenarios categorised as high or extreme risk.

Conclusion: We identified 131 extreme or high-risk prescribing scenarios that may be prevented using e-prescribing clinical decision support. The prescribing scenarios represent a variety of categories, with drug–disease contraindications being the most frequent, representing 37 (27%) scenarios, and antimicrobial agents being the most common drug class, representing 28 (21%) of the scenarios. Our e-Delphi study has achieved expert consensus on the risk associated with a range of clinical scenarios with most of the scenarios categorised as extreme or high risk. These prescribing scenarios represent the breadth of preventable prescribing error categories involving both basic and advanced clinical decision support. We will use the findings of this study to inform the development of the e-prescribing risk and safety evaluation tool.

KEYWORDS
medication errors, patient safety, prescribing, quality use of medicines
1 | INTRODUCTION

1.1 | Background and significance

The World Health Organization’s (WHO) third global patient safety challenge aims to reduce severe, medication-related harm by 50% over 5 years, by strengthening prescribing systems at each stage of the medication process, including prescribing, ordering, dispensing, administering and monitoring.3 e-Prescribing (EP) has been defined as “the utilisation of electronic systems to facilitate and enhance the communication of a prescription or medicine order, aiding the choice, administration and supply of a medicine through knowledge and decision support and providing a robust audit trail for the entire medicines use process”.5 The benefits of EP systems combined with clinical decision support (CDS) systems are well documented and include a reduction in medication errors and preventable adverse events.3–5 Prescribing errors can continue to decrease over time as users adapt to the system and system configuration is optimised for local use.6 Greater patient safety benefits are observed with experienced users rather than new implementers.7 Slight et al. investigated the impact of system optimisation in a prospective observational study in a large UK hospital and reported how some types of errors reduced over time, with serial changes made to the system.8 Clearly, optimal system configuration is required to maximise benefits.

Implementation of EP has also been shown to be associated with the introduction of new types of errors often referred to as the unintended consequences of EP.9 A systematic review identified eight error categories associated with EP systems that related to both system design and user–system interactions.10 Overuse of alerts or inappropriate alerting results in alert fatigue and a high incidence of alert overrides, which can adversely affect patient safety.11 Van de Sijs et al. reviewed the efficacy of alerts and found an override rate of between 49 and 96%, with low-level alerts overridden more frequently than high-level alerts.12 Slight et al. concluded that 5.5 million alerts are inappropriately overridden in the United States each year, which is associated with a related cost of between $871 million and $1.8 billion from preventable adverse drug events.13

The UK government has launched several funding initiatives to drive digital advancement within National Health Service (NHS) organisations, including the implementation and optimisation of EP systems, which has resulted in increased uptake in recent years.14 In 2013, Ahmed et al. reported that in response to a national survey of EP usage, more than two-thirds of NHS hospitals had implemented at least one EP system, with many hospitals utilising multiple different EP systems; 60 different systems were operational across the respondent hospitals.15 In September 2020, EP systems have been implemented in over 130 NHS trusts.16

In the United States, simulation tools have been used to evaluate e-prescribing systems; the Leapfrog computerised physician order entry (CPOE) evaluation tool is probably one of the best-known ones and assesses hospital safety, quality and efficiency based on national performance measures.17 The annual Leapfrog Hospital survey is voluntary and freely available to hospitals throughout the United States, with the results publicly reported. Participating hospitals are provided with information that benchmarks their progress towards improving patient care. The Leapfrog CPOE evaluation tool has been used to inform system configuration development, leading to improved system safety.18 Variability in safety performance has been demonstrated between different hospital EP systems, independent of system vendor.19 Uptake of the Leapfrog CPOE evaluation tool has increased 10-fold over the last decade; however, longitudinal data has demonstrated only modest improvements in electronic health record (EHR) safety performance and the persistence of substantial safety risks.20

There is currently no standard method to evaluate the effectiveness of implemented EP systems in preventing medication errors or adverse drug events in the UK. Resources are available to support NHS hospitals in the implementation and optimisation of EP systems including “how to” guides and examples of good practice, but opportunities to test and receive feedback on system configuration is not currently available. The development of an e-Prescribing Risk and Safety Evaluation tool (ePRaSE) has been commissioned by NHSX, which is a UK Government organisation responsible for the delivery and expansion of digital healthcare within NHS settings. Similar to the US Leapfrog tool,19 ePRaSE is a web-based tool designed to evaluate the capabilities available in electronic prescribing systems that are currently being used in UK hospitals. The assessment methodology offers a one-time, cross-sectional look at whether decision support provides advice to a prescriber. The ePRaSE tool uses test patients (i.e., fictitious patients) and test orders, which represent actual

What is already known about this subject

- Implementation of e-prescribing (EP) reduces preventable adverse drug events; however, optimal system configuration is required to maximise benefits.
- In the United States, simulation tools have been used to evaluate the safety of EP systems
- High-risk prescribing scenarios are used by healthcare professionals, to promote safer use of medicines

What this study adds

- This study has identified high-risk prescribing scenarios amenable to clinical decision support and appropriate for use in the development of the e-Prescribing Risk and Safety Evaluation tool (ePRaSE)
- This simulation tool will be rolled out, nationally, to all NHS organisations with implemented EP systems, to support optimisation.
medication orders and include high-risk prescribing scenarios that not only have potential to cause patient harm, but also could be prevented using EP systems. The ePRaSE tool is designed to give individual hospitals detailed and specific feedback on their safety performance.

1.2 | Objectives

Our aim was to establish expert consensus on the high-risk prescribing scenarios which are appropriate for use in the development of a UK simulation tool (the e-Prescribing Risk and Safety Evaluation tool (ePRaSE)) that will be rolled out to all NHS organisations with implemented EP systems in England.

2 | METHOD

The e-Delphi technique is a structured process for assembling knowledge from a group of experts to achieve consensus on a specific theme. Where there is a lack of empirical evidence, the Delphi technique provides an opportunity to gather opinion from experts who may be located in geographically different regions and settings.21 The e-Delphi technique has been commonly adopted in healthcare research, including similar clinical informatics research.21,22 Sweidan et al. utilised a modified Delphi technique to establish consensus on the features of e-prescribing systems that are expected to support the safety and quality of prescribing practices and use of medicines in general practice.22

2.1 | Development of the clinical scenarios

We conducted a literature search to identify clinical scenarios that relate to medication errors amenable to clinical decision support, which occurred with reasonable frequency within UK adult and paediatric inpatient populations.

Twenty-two published papers were identified; many of the scenarios were primary care focused or contained incidents of inappropriate prescribing and potential prescribing omissions largely based on STOP/START23 and Beers criteria.24 Thomas et al. identified 80 high-risk prescribing errors agreed by experts to result in possible patient harm.25 A related study by Fox et al. identified 41 prescribing indicators relevant to the paediatric inpatient setting.26 Both studies were conducted in the UK and included prescribing scenarios amenable to clinical decision support, which were highly relevant to this study. Other sources were utilised to identify relevant clinical scenarios including National Reporting and Learning System (NRLS) reports (n = 7), National Patient Safety Agency (NPSA) alerts (n = 6) and Medicines and Healthcare products Regulatory Agency (MHRA) guidance (n = 3). After removal of duplicates, we extracted a final list of 170 clinical scenarios, which were presented to the Expert Panel as a statement. See Box 1 for further details. The statement described a potential prescribing error with an explanation of the significance of the error in brackets.

BOX 1: Example clinical indicators as presented in the e-Delphi survey

Scenario 1. Low molecular weight omitted to be prescribed for prophylaxis when indicated (risk of venous thromboembolism)

Scenario 2. Atazanavir prescribed concomitantly with proton pump inhibitor (risk of atazanavir treatment failure)

2.2 | The e-Delphi process

We set out to pilot our e-Delphi survey first with a small group (n = 7), before asking our Expert Panel to complete a two-round e-Delphi survey, and have summarised the process in the accompanying flow chart (see Appendix).

2.2.1 | Participants

Forty-five experts were identified and invited to participate in the e-Delphi study based on their expertise in medication safety and clinical informatics. The experts were known to the ePRaSE project board and included a range of UK healthcare professionals such as doctors (n = 10), nurses (n = 3), pharmacists (n = 31) and pharmacy technicians (n = 1), employed in a variety of health care settings and across a breadth of UK geographical locations.

2.2.2 | e-Delphi pilot

Prior to the launch of the e-Delphi, a pilot was conducted to explore the suitability and usability of the survey. We invited seven senior clinical pharmacists, representing a range of clinical specialities, to participate in the pilot, sending them a link to the online survey. These pharmacists were not invited to be on the Expert Panel. All seven participants completed the survey and attended a group meeting at which they provided useful feedback on the suitability and readability of the clinical scenarios. Overall, the pilot e-Delphi participants reported the scenarios were appropriate and clearly presented. Changes to the wording of two of the scenarios were made to improve clarity. Pilot participants raised concerns about the potential for external factors to influence the level of...
harm, such as dose adjustments recommended in renal impairment as these may be dependent on the presentation of the disease (whether acute or chronic) and the age of the patient. These concerns were fed back to ePRaSE board who acknowledged this. The e-Delphi was presented as one continuous document and the pilot participants also reported that they were unable to save answers until the end, which was inconvenient. The survey was amended and scenarios separated by error category, thus allowing answers to be saved after each section. Three additional scenarios were suggested by the pilot participants for inclusion, resulting in a total of 173 scenarios in the final survey. The participants also recommended the addition of a “don’t know” option for each risk score, as they felt that this would allow participants to provide answers related only to their expertise.

**Defining the ePRaSE risk score**

Initially, participants were asked to assign two risk scores to each prescribing scenario based on the National Reporting and Learning System (NRLS) risk matrix, which utilises a numerical rating scale to relate the likelihood of an event (1–5) and the level of harm 1 (insignificant) – 5 (catastrophic).26 Pilot e-Delphi participants reported a number of challenges with this, as the likelihood of the event and consequent harm occurring was subject to interpretation. For example, taking the clinical scenarios 1 (Box 1), participants reported that the prescribing event occurs frequently and the patient harm occurs infrequently, but the associated harm could be major. For scenario 2 (Box 1), the prescribing event would occur infrequently and patient harm is extremely likely, but the associated harm could also be major. Both of these clinical scenarios are significant for different reasons. Consequently, participants were asked to use a revised scoring system, adapted from the NRLS, but with three dimensions as described in Table 1.

![](https://www.aacrjournals.org/doi/abs/10.1158/1535-7163.EPCP-18-0445)

**Table 1**  
Table: ePRaSE risk scoring system adapted from NRLS risk score matrix

| Likelihood of occurrence of the prescribing event | Level of harm associated with the prescribing event | Likelihood of harm occurrence |
|-----------------------------------------------|-----------------------------------------------|-----------------------------|
| 5. Very likely to occur on many occasions (e.g., at least once per month) | 5. Catastrophic – Incident causing death | 5. Very likely to occur on many occasions (e.g., at least once per month) |
| 4. Likely to occur but not every day (e.g., quarterly) | 4. Major – Incident that contributed to, but not the direct cause of death | 4. Likely to occur but not every day (e.g., quarterly) |
| 3. May occur occasionally (e.g., at least annually) | 3. Moderate–semi-permanent harm taking 1 month to 1 year to resolve or requires a hospital stay | 3. May occur occasionally (e.g., at least annually) |
| 2. Unlikely to occur, but possible (e.g., once every 5 years) | 2. Minor – Short term harm, less than 1 month or requiring additional monitoring | 2. Unlikely to occur but possible (e.g., once every 5 years) |
| 1. Very unlikely to occur (once in a decade/not at all) | 1. Insignificant – Near miss or no harm to the patient. | 1. Very unlikely to occur (once in a decade/not at all) |

**2.3 Round 1 (exploratory)**

The e-Delphi survey was presented to the Expert Panel via an online survey platform on 1 October 2018; background information was provided following a consent statement, which required completion prior to accessing the e-Delphi survey. Participants were asked to rate the risk associated with each scenario, utilising the revised risk score, and comment on the suitability and wording of the scenarios. They could also suggest additional scenarios for inclusion. Participants were kindly requested to complete the survey within 2 weeks. On completion, the potential risk and actual risk score were calculated for each participant response and median scores were calculated for each scenario. The percentage of participant consensus with the median risk score was calculated.

**2.4 Round 2**

The second round utilised a modified survey, excluding both (a) the scenarios where consensus had been achieved, defined as ≥70% participant consensus28 for actual or potential harm risk score, and (b) scenarios with no consensus, which we defined as less than 50% consensus with the median score on both risk scores. We included new scenarios suggested by the expert participants. Participants were provided with their own individual risk scores from the first round and the median scores for each scenario. This provided the participants with an opportunity to modify their responses, in light of the judgments made by the rest of the Expert Panel, or to retain their original risk scores if deemed appropriate.

**3 RESULTS**

Of the 45 experts who were invited to participate, 24 consented to participate. Fifteen participants completed Round 1 of the e-Delphi
and 13 participants completed Round 2. The professional groups of the experts who completed each round are outlined in Table 2. Participants’ additional roles included e-prescribing/informatics leads and both national and regional roles in medication safety.

3.1 | Round 1

All 15 experts agreed on the category of risk for 51 of the 173 scenarios presented. Thirty-seven scenarios achieved low levels of consensus. Of the 11 scenarios that participants suggested should be added, five were included in Round 2. Of the remaining six scenarios suggested, four duplicated some of the themes already represented and two represented error categories that were already well represented. In total, 90 scenarios were taken forward to Round 2.

3.2 | Round 2

Thirteen participants completed the survey and consensus was achieved for a further 85 out of 90 scenarios; it was therefore not considered necessary to proceed to Round 3. Consensus was not achieved for both actual and potential harm for five scenarios which included a range of scenario categories; drug–drug interactions \((n = 1)\), drug–dose \((n = 1)\), drug–laboratory test \((n = 1)\) and drug–brand \((n = 2)\).

In total, expert consensus was reached on the risk category of 136 out of 178 scenarios across both e-Delphi rounds. Of these, four scenarios were classed as extreme risk with a median potential or actual risk score between 15 and 25, 127 scenarios were classed as high risk with a median risk score of between 8 and 12, and five scenarios were classed as low or moderate risk with a median risk score

### Table 2

| Profession                        | Round 1 \((n = 15)\) | Round 2 \((n = 13)\) |
|----------------------------------|-----------------------|----------------------|
| Doctor                           | 2                     | 1                    |
| Nurse (informatics)              | 1                     | 1                    |
| Pharmacist                       | 11                    | 10                   |
| Pharmacy technician (informatics)| 1                     | 1                    |

### Table 3

#### Example scenarios with risk category and consensus scores

| Scenario category | Scenario description                                                                 | Median risk score | Risk category | Percentage consensus with median |
|-------------------|--------------------------------------------------------------------------------------|-------------------|---------------|----------------------------------|
| Drug–allergy      | Any medication prescribed for a patient with a documented allergy to the medication (risk of severe adverse drug reaction) | 16.0              | Extreme       | 90                               |
| Drug–drug interaction | Potassium-sparing diuretic (excluding aldosterone antagonists) prescribed concomitantly with angiotensin-converting enzyme inhibitor or angiotensin II receptor antagonist (increased risk of severe hyperkalaemia) | 12.0              | High          | 100                              |
| Drug–age contraindication | Tetracycline prescribed to a child under 12 years (may result in deposition in growing bone and teeth causing staining/dental hypoplasia) | 6.0               | Low/moderate  | 88                               |

### Table 4

#### Prescribing scenario categories for extreme or high-risk scenario

| Prescribing scenario category | Number of extreme or high risk scenarios | Drug class                  | Number of extreme or high risk scenarios |
|-------------------------------|-----------------------------------------|-----------------------------|-----------------------------------------|
| Drug–allergy                  | 2                                       | Analgesics (including opioids) | 12                                      |
| Drug–age                      | 11                                      | Anticoagulants              | 11                                      |
| Drug–brand                    | 3                                       | Antimicrobial               | 28                                      |
| Drug–lab                      | 24                                      | Cardiovascular system       | 17                                      |
| Drug–drug interactions        | 27                                      | Central nervous system       | 13                                      |
| Drug–disease                  | 37                                      |                             |                                         |
| Drug–dose                     | 18                                      |                             |                                         |
| Drug–omissions                | 4                                       |                             |                                         |
of <8. An example of scenarios classified as extreme risk, high risk and low or moderate risk are provided in Table 3.

There were very few scenarios classified as extreme risk ($n = 4$), which included drug-allergy scenarios and scenarios relating to safe prescribing of anticoagulants. The most common categories represented include drug–disease scenarios ($n = 37$), drug–drug interactions ($n = 25$), and drug–laboratory tests ($n = 24$). The categories of the extreme and high-risk scenarios are described in Table 4.

4 | DISCUSSION

This e-Delphi study established expert consensus on the level of risk associated with 136 out of a total of 178 clinical scenarios, with the majority of scenarios categorised as high-risk. We plan to use these scenarios in the development of the ePRaSE tool, as they cover a wide range of clinical events and are amenable to clinical decision support. This includes both basic clinical decision support, such as drug–drug interactions (DDIs), drug–allergy identification, therapeutic duplication and basic dosage recommendations as well as advanced clinical decision support such as renal and age-related dosing advice; drug–disease contraindications and advice relating to corollary tests. The most common categories represented in the e-Delphi survey included drug–disease contraindications, drug–drug interactions and scenarios involving drug–laboratory test interventions, which represent the categories of clinical decision support with the greatest volume of evidence related to change in prescriber behaviour and improved patient safety.

The drug–drug interactions identified as high-risk in this study show some similarities and some differences with previous published high priority drug–drug interactions. Phansalkar et al. gained consensus regarding high priority drug–drug interactions in a US setting, therefore differences in prescribing rates may, in part, explain the different priorities obtained by experts in the UK. Some of our drug–drug categories reflected themes identified in a systematic review and meta-analysis of drug–drug interactions associated with hospital admission/visits, such as interactions resulting in increased risk of bleeding complications and interactions associated with prolongation of the QT interval, but a similarity in the specific drug–drug interactions was not observed. This lack of consistency reflects the subjective nature of drug–drug interaction categorisation.

There are challenges associated with the prevention of high-risk prescribing errors involving drug–disease contraindications and drug–laboratory tests utilising advanced clinical decision support. Interaction with other components of the health record is required, in particular the EHR and laboratory information management system (LIMS), to access the clinical data required. Many different EP systems are employed in NHS hospitals, with some hospitals utilising several systems concurrently. Some hospitals employ integrated EP systems, which form a component of the EHR, whereas others employ stand-alone EP systems used in isolation or combined with other stand-alone packages. Consequently, these different information technology and software applications need to be able to communicate, exchange and use data accurately and effectively (system interoperability). There are substantial benefits associated with improving access to complete and accurate patient records and enhancing communication between healthcare professionals; however, barriers to system interoperability persist due to the complexity of the healthcare domain, system incompatibilities and resistance to change. In addition, the information regarding drug–disease contraindications listed in the electronic Medicines Compendium Summaries of Product Characteristics is vast, and so prioritisation is required to avoid over-alerting and associated alert fatigue.

A systematic review of the incidence, causes and consequences of preventable adverse drug reactions occurring in inpatients reported cardiovascular drugs, analgesics, anticoagulants, opioids and antibiotics/anti-infective agents to be the drug classes most frequently associated with preventable adverse events. Our study included medications from all of these classes, with scenarios involving antimicrobial therapies most commonly represented. This is also consistent with other studies that identify prescribing scenarios amenable to clinical decision support. Many of the scenarios involve high-risk medicines, which, by definition, are more likely to cause significant patient harm. A recent systematic review concluded that clinical decision support can improve the safe use of high-risk medicines like anticoagulants with both improved adherence to guidelines, and increased therapeutic drug monitoring reported. In addition, EP with clinical decision support is perceived to be a key enabler of the implementation of antimicrobial stewardship initiatives to reduce global antimicrobial resistance.

4.1 | Limitations

Our study has a few limitations. Firstly, the number of expert participants who completed both rounds of the e-Delphi was lower than anticipated. Although the number of participants recruited to a Delphi study in the literature can be anywhere between 10 and 50, a response rate of ≥70% should be maintained. Fifteen participants completed Round 1 and 13 completed Round 2, which equates to a response rate of 60% and 52% respectively. Our low overall response rate may have been associated with the number of scenarios we included, which represented a considerable time commitment for participants. This hypothesis is supported by research that suggests Delphi studies with higher numbers of items are associated with significantly lower response rates. Although the response rate was lower than expected, retention of participants between Round 1 and Round 2 was 87%, which improves the reliability of the findings. Secondly, 42 of the scenarios presented to the expert participants did not achieve a consensus. This included scenarios that were classified as high risk by some participants. These scenarios were not incorporated into the ePRaSE tool, however, may represent significant prescribing safety concerns. Thirdly, the experts invited to participate in the e-Delphi included a range of healthcare professionals from across the UK; however, pharmacists were over-represented in the final sample with pharmacists representing 59% and 69% of participants in Rounds 1 and
2, respectively. Further research involving a diverse range of prescribers could be recommended to strengthen the findings and gain consensus on the risk represented by the remaining 42 scenarios.

Fourthly, in Round 2, participants were provided with their individual risk scores from Round 1 along with median scores for each prescribing scenario. This could potentially bias their responses in Round 2. Fifthly, we developed a risk score based on the likelihood of the prescribing event, level of harm and likelihood of harm. Variability in interpretation is likely, based upon participants’ personal characteristics and experiences. Finally, the study was carried out in the UK to inform the development of an e-prescribing risk and safety evaluation tool to be used within UK hospitals, and so the findings may not be generalisable beyond the UK.

5 | CONCLUSION
The e-Delphi technique has been used to reach consensus on a set of high-risk prescribing scenarios to be used to inform the development of a simulation tool to evaluate the safety of e-prescribing systems in the UK. The scenarios represent prescribing events frequently associated with patient harm, including high-alert medication and antimicrobial therapies, and address key concepts in e-prescribing system optimisation such as improving patient specificity and promoting system interoperability. As well as providing individual feedback to NHS hospitals, national data will identify good performance to promote shared learning. Regular review of this list will be required to ensure continuing clinical relevance and to identify new emerging prescribing risks.

ACKNOWLEDGMENTS
The authors wish to thank the following people who contributed to this study. ePRaSE Board members: Andrew Heed and Graeme Kirkpatrick who contributed to both the design and delivery of the study and the expert panel members who participated in the e-Delphi study. The study was conducted as part of a PhD programme of work, funded by Newcastle University and Newcastle Upon Tyne Hospitals NHS Trust. The study was conducted as part of a PhD programme of work, funded by Newcastle University and Newcastle Upon Tyne Hospitals NHS Trust.

COMPETING INTERESTS
The authors report there are no conflicts of interest to declare.

CONTRIBUTORS
N.W. and A.S. conceived the presented idea. J.H. and S.K. developed the e-Delphi and analysed the results. J.H., S.P.S. and A.H. wrote the manuscript. All authors discussed the results and approved the final manuscript.

DATA AVAILABILITY STATEMENT
The datasets generated during the current study are not publicly available, to maintain the integrity of the e-prescribing risk and safety evaluation (ePRaSE) assessment, which the data has been used to develop.

ORCID
Jude Heed https://orcid.org/0000-0001-6046-6011

REFERENCES
1. World Health Organization. WHO global patient safety challenge: medication without harm. Geneva: WHO; 2017. Available at: http://www.who.int/patientsafety-medication-safety/en/.
2. NHS Connecting for Health. Electronic Prescribing in Hospitals, Challenges and Lessons Learnt. 2009. Available at: http://webarchive.nationalarchives.gov.uk/20130502102046/http://www.connectingforhealth.nhs.uk/systemsandservices/eprescribing/challenges/Final_report.pdf. Accessed July 2020.
3. Ammenwerth E, Schnell-Inderst P, Machan C, Siebert U. The effect of electronic prescribing on medication errors and adverse drug events: a systematic review. J Am Med Inform Assoc. 2008;15(5):585-600. doi:10.1197/jamia.M2667
4. Radley DC, Wasserman MR, Olsho LEW, Shoemaker SJ, Spranca MD, Bradshaw B. Reduction in medication errors in hospitals due to adoption of computerized provider order entry systems. J Am Med Inform Assoc. 2013;20(3):470-476. doi:10.1197/amiajnl-2012-001241
5. Nuckols TK, Smith-Spangler C, Morton SC, et al. The effectiveness of computerized order entry at reducing preventable adverse drug events and medication errors in hospital settings: a systematic review and meta-analysis. Syst Rev. 2014;3(1):56. doi:10.1186/2046-4053-3-56
6. Abramson EL, Malhotra S, Osorio SN, et al. A long-term follow-up evaluation of electronic health record prescribing safety. J Am Med Inform Assoc. 2013;20(e1):e52-e58. doi:10.1197/amiajnl-2012-001328
7. Ranji SR, Renne S, Wachter RM. Computerized provider order entry combined with clinical decision support systems to improve medication safety: a narrative review. BMJ Qual Saf. 2014;23(9):773-780.
8. Slight S, Tolley C, Bates D, et al. Medication errors and adverse drug events in a UK hospital during the optimisation of electronic prescribings: a prospective observational study. Lancet Digital Health. 2019;1(8):e403-e412. doi:10.1016/S2589-7500(19)30158-X
9. Koppel R, Metlay JP, Cohen A, et al. Role of computerized physician order systems in facilitating medication errors. JAMA. 2005;293(10):1197-1203. doi:10.1001/jama.293.10.1197
10. Brown CL, Mulcaster HL, Triffitt KL, et al. A systematic review of the types and causes of prescribing errors generated from using computerized provider order entry systems in primary and secondary care. J Am Med Inform Assoc. 2017;24(2):432-440. doi:10.1093/jamia/ocw119
11. Meeks DW, Smith MW, Taylor L, Sittig DF, Scott JM, Singh H. An analysis of electronic health record-related patient safety concerns. J Am Med Inform Assoc. 2014;21(6):1053-1059. doi:10.1197/jamiaocw.2013-002578
12. Van der Sijs H, Aarts J, Vulto A, Berg M. Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc. 2006;13(2):138-147. doi:10.1197/jamia.M1809
13. Slight SP, Seger DL, Franz C, Wong A, Bates DW. The national cost of adverse drug events resulting from inappropriate medication-related alert overrides in the United States. J Am Med Inform Assoc. 2018;25(9):1183-1188. doi:10.1093/jamia/ocy066
14. NHS. The NHS Long Term Plan. 2019. Available at: https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf. Accessed July 2020.
15. Ahmed Z, McLeod MC, Barber N, Jacklin A, Franklin BD. The use and functionality of electronic prescribing systems in English acute NHS Trusts: a cross-sectional survey. PLoS ONE. 2013;8(11):e80378. doi:10.1371/journal.pone.0080378

16. Department of Health. New funding to help hospitals introduce digital prescribing [press release]. 17 September 2020. Available at: https://www.gov.uk/government/news/new-funding-to-help-hospitals-introduce-digital-prescribing. Accessed February 23, 2022.

17. The Leapfrog group. Available at: https://www.leapfroggroup.org/. Accessed July 2020.

18. Leung AA, Keohane C, Lipsitz S, et al. Relationship between medication event rates and the Leapfrog computerized physician order entry evaluation tool. J Am Med Inform Assoc. 2013;20(1):e85-e90. doi:10.1136/amiajnl-2012-001549

19. Metzger J, Welebob E, Bates D, Lipsitz S, Classen D. Mixed results in the safety performance of computerized physician order entry. Health Aff. 2010;29(4):655-663. doi:10.1377/hlthaff.2010.0160

20. Classen DC, Holmgren AJ, Co Z, et al. National trends in the safety performance of electronic health record systems from 2009 to 2018. JAMA Netw Open. 2020;3(5):e205547. doi:10.1001/jamanetworkopen.2020.5547

21. Trevelyan EG, Robinson PN. Delphi methodology in health research: how to do it? Eur J Integrat Med. 2015;7(4):423-428. doi:10.1109/j. ejium.2015.07.002

22. Sweeney M, Williamon M, Reeve JF, et al. Identification of features of electronic prescribing systems to support quality and safety in primary care using a modified Delphi process. BMC Med Inform Decis Mak. 2010;10(1):21. doi:10.1186/1472-6947-10-21

23. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213-218. doi:10.1093/ageing/afu145

24. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geniatr Soc. 2015;63(11):2227-2246. doi:10.1111/jgs.13702

25. Thomas SK, McDowell SE, Hodson J, et al. Developing consensus on hospital prescribing indicators of potential harms amenable to decision support. Br J Clin Pharmacol. 2013;76(5):797-809. doi:10.1111/bcp.12087

26. Fox A, Pontefract S, Brown D, Portlock J, Coleman J. Developing consensus on hospital prescribing indicators of potential harm for infants and children. Br J Clin Pharmacol. 2016;82(2):451-460. doi:10.1111/bcp.12954

27. National Patient Safety Agency. A risk matrix for risk managers. 2008. Available at: https://silos.tips/download/a-risk-matrix-for-risk-managers. Accessed February 23, 2022.

28. Keeney S, McKenna H, Hasson F. The Delphi Technique in Nursing and Health Research. Chichester: Wiley-Blackwell; 2010.

29. Kuperman GJ, Bobb A, Payne TH, et al. Medication-related clinical decision support in computerized provider order entry systems: a review. J Am Med Inform Assoc. 2007;14(1):29-40. doi:10.1197/jamia.M2170

30. Veeren JC, Weiss M. Trends in emergency hospital admissions in England due to adverse drug reactions: 2008–2015. J Pharm Health Serv Res. 2017;8(1):5-11. doi:10.1111/jphs.12160

31. Page N, Baysari MT, Westbrook JI. A systematic review of the effectiveness of interruptive medication prescribing alerts in hospital CPOE systems to change prescriber behaviour and improve patient safety. Int J Med Inform. 2017;105:22-30. doi:10.1016/j.jmedinf.2017.05.011

32. Phansalkar S, Wright A, Kuperman GJ, et al. Towards meaningful medication-related clinical decision support: recommendations for an initial implementation. Appl Clin Inform. 2011;2(1):50-62. doi:10.4338/ACI-2010-04-RA-0026

33. Dechantan S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23(5):489-497. doi:10.1002/pds.3592

34. Ohlund S-E, Astrand B, Petersson G. Improving interoperability in e-prescribing. Interact J Med Res. 2013;2(1):e17. doi:10.2196/ijmr.2089

35. Tolley CL, Slight SP, Husband AK, Watson N, Bates DW. Improving medication-related clinical decision support. Am J Health Syst Pharm. 2018;75(4):239-246. doi:10.2146/ajhp160830

36. Czock D, Konias M, Seidling HM, et al. Tailoring of alerts substantially reduces the alert burden in computerized clinical decision support for drugs that should be avoided in patients with renal disease. J Am Med Inform Assoc. 2015;22(4):881-887. doi:10.1093/jamia/ocv027

37. Wolfe D, Yazdi F, Kanji S, et al. Incidence, causes, and consequences of preventable adverse drug reactions occurring in inpatients: a systematic review of systematic reviews. PLoS ONE. 2018;13(10):e0205426. doi:10.1371/journal.pone.0205426

38. Institute for Safe Medication Practices. High-Alert Medications in Acute Care Settings. 2018. Available at: https://www.ismp.org/recommendations/high-alert-medications-acute-list. Accessed July 2020.

39. Sennesael A-L, Krug B, Sneyers B, Spinewine A. Do computerized clinical decision support systems improve the prescribing of oral anticoagulants? A systematic review. Thromb Res. 2020;187:79-87. doi:10.1016/j.thromres.2019.12.023

40. World Health Organization. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics [online]. 2017. Available at: https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Accessed July 2020.

41. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008-1015.

42. Gargon E, Crew R, Burnside G, Williamson PR. Higher number of items associated with significantly lower response rates in COS Delphi surveys. J Clin Epidemiol. 2019;108:110-120. doi:10.1016/j.jclinepi.2018.12.010

How to cite this article: Heed J, Klein S, Slee A, Watson N, Husband A, Slight SP. An e-Delphi study to obtain expert consensus on the level of risk associated with preventable e-prescribing events. Br J Clin Pharmacol. 2022;88(7):3351-3359. doi:10.1111/bcp.15284
## APPENDIX A

### The Delphi Process

| STAGE | PROCESS | RESULTS |
|-------|---------|---------|
| Defining the problem | Which patient prescribing errors should be prioritised by clinical decision support? | 170 prescribing scenarios identified |
| | • What are the published prescribing scenarios that identify errors amenable to clinical decision support? | |
| | • What prescribing errors can be identified through local or national medication safety initiatives? | |
| e-Delphi pilot | 7 clinical pharmacists completed e-Delphi and asked to: | Lack of clarity reported for 3 scenarios |
| | • Review the scenarios and comment on the clarity and relevance | 1 additional scenario suggested (total 173) |
| | • Comment on the feasibility of the e-Delphi survey | |
| | • Suggest additional prescribing scenarios | |
| Expert panel | Experts in medication safety and clinical informatics | 45 experts verbally agree to participate |
| | • UK based practitioners | 74 provided written consent; 15 completed round 1 and 13 completed round 2. |
| | • Agree to timescales | |
| Round 1 | Participants asked to rate each indicator for likelihood of occurrence of prescribing event, severity of harm associated with prescribing event and likelihood of harm occurrence | Median score consensus for all scenarios <70% |
| | Participants asked for comments and suggestions for further scenarios | e-Delphi proceeds to round 2 |
| | Potential and actual harm: risk scores calculated and median scores determined for each scenario | Scenarios excluded from round 2 when median consensus achieved (n = 55) and when no consensus achieved (n = 3) |
| | Scenarios categorised as low (1-3); moderate (4-6); high (8-12) and extreme risk (15-25), based on the median. | 11 scenarios suggested, 3 included following review. 90 scenarios taken in to round 2 |
| | Consensus calculated for each scenario as percentage of participants with the same risk classification as the median (defined as ≥70%) | |
| Round 2 | 90 scenarios returned to participants with their scores from round one and median round one scores from all participants | Median score consensus recalculated for all scenarios ≥70% |
| | Participants able to change their scores in light of round one median scores or to retain their original viewpoints | Consensus achieved for 136 out of 178 scenarios |